|
1
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fearon ER and Vogelstein B: A genetic
model for colorectal tumorigenesis. Cell. 61:759–767. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yokoyama N, Hayashi N, Seki T, Panté N,
Ohba T, Nishii K, Kuma K, Hayashida T, Miyata T and Aebi U: A giant
nucleopore protein that binds Ran/TC4. Nature. 376:184–188. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Murrin LC and Talbot JN: RanBPM, a
scaffolding protein in the immune and nervous systems. J
Neuroimmune Pharmacol. 2:290–295. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Salemi LM, Loureiro SO and Schild-Poulter
C: Characterization of RanBPM molecular determinants that control
its subcellular localization. PLoS One. 10:e01176552015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang H, Lewsadder M, Dorn E, Xu S and
Lakshmana MK: RanBP9 overexpression reduces dendritic arbor and
spine density. Neuroscience. 265:253–262. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang R, Palavicini JP, Wang H, Maiti P,
Bianchi E, Xu S, Lloyd BN, Dawson-Scully K, Kang DE and Lakshmana
MK: RanBP9 overexpression accelerates loss of dendritic spines in a
mouse model of Alzheimer's disease. Neurobiol Dis. 69:169–179.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Valiyaveettil M, Bentley AA, Gursahaney P,
Hussien R, Chakravarti R, Kureishy N, Prag S and Adams JC: Novel
role of the muskelin-RanBP9 complex as a nucleocytoplasmic mediator
of cell morphology regulation. J Cell Biol. 182:727–739. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rex EB, Rankin ML, Yang Y, Lu Q, Gerfen
CR, Jose PA and Sibley DR: Identification of RanBP 9/10 as
interacting partners for protein kinase C (PKC) gamma/delta and the
D1 dopamine receptor: Regulation of PKC-mediated receptor
phosphorylation. Mol Pharmacol. 78:69–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao Z, Cheng S, Zabkiewicz C, Chen J,
Zhang L, Ye L and Jiang WG: Reduced expression of ranBPM is
associated with poorer survival from lung cancer and increased
proliferation and invasion of lung cancer cells in vitro.
Anticancer Res. 37:4389–4397. 2017.PubMed/NCBI
|
|
11
|
Shao S, Sun PH, Satherley LK, Gao X, Ji
KE, Feng YI, Jia Y, Ji J, Jiang WG and Ye L: Reduced ranBPM
expression is associated with distant metastasis in gastric cancer
and chemoresistance. Anticancer Res. 36:1295–1303. 2016.PubMed/NCBI
|
|
12
|
Dai H, Lv YF, Yan GN, Meng G, Zhang X and
Guo QN: RanBP9/TSSC3 complex cooperates to suppress anoikis
resistance and metastasis via inhibiting Src-mediated Akt signaling
in osteosarcoma. Cell Death Dis. 7:e25722016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhu LL, Wang CH, Yang HP and Shu WH:
Expression of cartilage antitumor component RanBP9 in osteosarcoma.
J Biol Regul Homeost Agents. 30:103–110. 2016.PubMed/NCBI
|
|
14
|
Emberley ED, Gietz RD, Campbell JD,
HayGlass KT, Murphy LC and Watson PH: RanBPM interacts with
psoriasin in vitro and their expression correlates with specific
clinical features in vivo in breast cancer. BMC Cancer. 2:282002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qin C, Ren L, Ji M, Lv S, Wei Y, Zhu D,
Lin Q, Xu P, Chang W and Xu J: CDKL1 promotes tumor proliferation
and invasion in colorectal cancer. Onco Targets Ther. 10:1613–1624.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang H, Yang R, Zhong L, Zhu XY, Ma PP,
Yang XQ, Jiang KL and Liu BZ: Location of NLS-RARalpha protein in
NB4 cell and nude mice. Oncol Lett. 13:2045–2052. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Meng X, Franklin DA, Dong J and Zhang Y:
MDM2-p53 pathway in hepatocellular carcinoma. Cancer Res.
74:7161–7167. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang MF, Zhang ZY, Fu J, Yang YF and Yun
JP: Correlation between expression of p53, p21/WAF1, and MDM2
proteins and their prognostic significance in primary
hepatocellular carcinoma. J Transl Med. 7:1102009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lustig B, Jerchow B, Sachs M, Weiler S,
Pietsch T, Karsten U, van de Wetering M, Clevers H, Schlag PM,
Birchmeier W and Behrens J: Negative feedback loop of Wnt signaling
through upregulation of conductin/axin2 in colorectal and liver
tumors. Mol Cell Biol. 22:1184–1193. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Malumbres M: Cyclin-dependent kinases.
Genome Biol. 15:1222014. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Morgan DO: Cyclin-dependent kinases:
Engines, clocks, and microprocessors. Annu Rev Cell Dev Biol.
13:261–291. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ogino S, Nosho K, Irahara N, Shima K, Baba
Y, Toyoda S, Chen L, Giovannucci EL, Meyerhardt JA and Fuchs CS: A
cohort study of cyclin D1 expression and prognosis in 602 colon
cancer cases. Clin Cancer Res. 15:4431–4438. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao P, Hu YC and Talbot IC: Expressing
patterns of p16 and CDK4 correlated to prognosis in colorectal
carcinoma. World J Gastroenterol. 9:2202–2206. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fry DW, Harvey PJ, Keller PR, Elliott WL,
Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK and
Toogood PL: Specific inhibition of cyclin-dependent kinase 4/6 by
PD 0332991 and associated antitumor activity in human tumor
xenografts. Mol Cancer Ther. 3:1427–1438. 2004.PubMed/NCBI
|
|
25
|
Aklilu M, Kindler HL, Donehower RC, Mani S
and Vokes EE: Phase II study of flavopiridol in patients with
advanced colorectal cancer. Ann Oncol. 14:1270–1273. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Motwani M, Rizzo C, Sirotnak F, She Y and
Schwartz GK: Flavopiridol enhances the effect of docetaxel in vitro
and in vivo in human gastric cancer cells. Mol Cancer Ther.
2:549–555. 2003.PubMed/NCBI
|
|
27
|
Yam CH, Fung TK and Poon RY: Cyclin A in
cell cycle control and cancer. Cell Mol Life Sci. 59:1317–1326.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zindy F, Lamas E, Chenivesse X, Sobczak J,
Wang J, Fesquet D, Henglein B and Bréchot C: Cyclin A is required
in S phase in normal epithelial cells. Biochem Biophys Res Commun.
182:1144–1154. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bloom J and Cross FR: Multiple levels of
cyclin specificity in cell-cycle control. Nat Rev Mol Cell Biol.
8:149–160. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lakshmana MK, Chung JY, Wickramarachchi S,
Tak E, Bianchi E, Koo EH and Kang DE: A fragment of the scaffolding
protein RanBP9 is increased in Alzheimer's disease brains and
strongly potentiates amyloid-beta peptide generation. FASEB J.
24:119–127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Brannetti B and Helmer-Citterich M: iSPOT:
A web tool to infer the interaction specificity of families of
protein modules. Nucleic Acids Res. 31:3709–3711. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang D, Li Z, Messing EM and Wu G: The
SPRY domain-containing SOCS box protein 1 (SSB-1) interacts with
MET and enhances the hepatocyte growth factor-induced
Erk-Elk-1-serum response element pathway. J Biol Chem.
280:16393–16401. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Woo JA, Roh SE, Lakshmana MK and Kang DE:
Pivotal role of RanBP9 in integrin-dependent focal adhesion
signaling and assembly. FASEB J. 26:1672–1681. 2012. View Article : Google Scholar : PubMed/NCBI
|
